KR101481164B1
(ko)
*
|
2008-01-30 |
2015-01-09 |
주식회사 미래셀바이오 |
체세포 유래 다능성 줄기세포의 제조 방법
|
KR102058946B1
(ko)
|
2011-04-08 |
2019-12-24 |
얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 |
바이러스 감염 치료를 위한 피리미딘 유도체
|
IN2014MN00862A
(me)
|
2011-11-09 |
2015-04-17 |
Janssen R & D Ireland |
|
UA113651C2
(xx)
|
2012-07-13 |
2017-02-27 |
|
Макроциклічні пурини для лікування вірусних інфекцій
|
DK2906563T3
(en)
|
2012-10-10 |
2018-06-06 |
Janssen Sciences Ireland Uc |
PYRROLO [3,2-D] PYRIMIDINE DERIVATIVES FOR TREATING VIRUS INFECTIONS AND OTHER DISEASES
|
PL2925729T3
(pl)
|
2012-11-16 |
2018-04-30 |
Janssen Sciences Ireland Uc |
Heterocykliczne podstawione pochodne 2-amino-chinazoliny do leczenia infekcji wirusowych
|
BR112015020118B1
(pt)
|
2013-02-21 |
2022-02-22 |
Janssen Sciences Ireland Uc |
Derivados de 2-aminopirimidina para o tratamento de infecções virais, composição farmacêutica e uso
|
HUE031908T2
(en)
|
2013-03-29 |
2017-08-28 |
Janssen Sciences Ireland Uc |
Macrocyclic deaza-purinones for the treatment of viral infections
|
US10377738B2
(en)
|
2013-05-24 |
2019-08-13 |
Janssen Sciences Ireland Unlimited Company |
Pyridone derivatives for the treatment of viral infections and further diseases
|
BR112015032546B1
(pt)
|
2013-06-27 |
2022-05-17 |
Janssen Sciences Ireland Uc |
Derivados de pirrolo[3,2-d]pirimidina e composição farmacêutica que os compreende para o tratamento de infecções virais e outras doenças
|
EA036162B1
(ru)
*
|
2013-07-30 |
2020-10-08 |
Янссен Сайенсиз Айрлэнд Юси |
Производные тиено[3,2-d]пиримидинов для лечения вирусных инфекций
|
CU20180011A7
(es)
*
|
2015-03-04 |
2018-06-05 |
Gilead Sciences Inc |
Composiciones farmacéuticas que comprenden compuestos derivados de diaminopirido (3,2-d) como moduladores de receptor de tipo toll
|
WO2017027350A2
(en)
|
2015-08-07 |
2017-02-16 |
Arrowhead Pharmaceuticals, Inc. |
Rnai therapy for hepatitis b virus infection
|
CA2995004A1
(en)
|
2015-08-26 |
2017-03-02 |
Gilead Sciences, Inc. |
Deuterated toll-like receptor modulators
|
JP2018527366A
(ja)
*
|
2015-09-15 |
2018-09-20 |
ギリアード サイエンシーズ, インコーポレイテッド |
HIVを処置するためのtoll様レセプターのモジュレーター
|
EP3992206A1
(en)
|
2015-12-15 |
2022-05-04 |
Gilead Sciences, Inc. |
Human immunodeficiency virus neutralizing antibodies
|
BR102017010009A2
(pt)
|
2016-05-27 |
2017-12-12 |
Gilead Sciences, Inc. |
Compounds for the treatment of hepatitis b virus infection
|
CA3025633C
(en)
|
2016-05-27 |
2021-02-23 |
Gilead Sciences, Inc. |
Methods for treating hepatitis b virus infections using ns5a, ns5b or ns3 inhibitors
|
MA45539A
(fr)
|
2016-07-01 |
2019-05-08 |
Janssen Sciences Ireland Unlimited Co |
Dihydropyranopyrimidines pour le traitement d'infections virales
|
JOP20170161A1
(ar)
|
2016-08-04 |
2019-01-30 |
Arrowhead Pharmaceuticals Inc |
عوامل RNAi للعدوى بفيروس التهاب الكبد ب
|
JOP20190024A1
(ar)
|
2016-08-26 |
2019-02-19 |
Gilead Sciences Inc |
مركبات بيروليزين بها استبدال واستخداماتها
|
ES2826748T3
(es)
|
2016-09-02 |
2021-05-19 |
Gilead Sciences Inc |
Derivados de 4,6-diamino-pirido[3,2-d]pirimidina como moduladores de receptores de tipo Toll
|
CA3035346A1
(en)
|
2016-09-02 |
2018-03-08 |
Gilead Sciences, Inc. |
Toll like receptor modulator compounds
|
US10968184B2
(en)
|
2016-09-29 |
2021-04-06 |
Janssen Sciences Ireland Unlimited Company |
Pyrimidine prodrugs for the treatment of viral infections and further diseases
|
PE20191353A1
(es)
|
2016-10-14 |
2019-10-01 |
Prec Biosciences Inc |
Meganucleasas disenadas especificamente para el reconocimiento de secuencias en el genoma del virus de la hepatitis b
|
AR110768A1
(es)
|
2017-01-31 |
2019-05-02 |
Gilead Sciences Inc |
Formas cristalinas de tenofovir alafenamida
|
JOP20180008A1
(ar)
|
2017-02-02 |
2019-01-30 |
Gilead Sciences Inc |
مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b
|
JP7169968B2
(ja)
|
2017-03-29 |
2022-11-11 |
住友ファーマ株式会社 |
ワクチンアジュバント製剤
|
JOP20180040A1
(ar)
|
2017-04-20 |
2019-01-30 |
Gilead Sciences Inc |
مثبطات pd-1/pd-l1
|
AR112413A1
(es)
|
2017-08-17 |
2019-10-23 |
Gilead Sciences Inc |
Formas sólidas de un inhibidor de la cápside del vih
|
AR112412A1
(es)
|
2017-08-17 |
2019-10-23 |
Gilead Sciences Inc |
Formas de sal de colina de un inhibidor de la cápside del vih
|
EP3672970A1
(en)
|
2017-08-22 |
2020-07-01 |
Gilead Sciences, Inc. |
Therapeutic heterocyclic compounds
|
WO2019084060A1
(en)
|
2017-10-24 |
2019-05-02 |
Silverback Therapeutics, Inc. |
CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS
|
EP3724222A1
(en)
|
2017-12-15 |
2020-10-21 |
Silverback Therapeutics, Inc. |
Antibody construct-drug conjugate for the treatment of hepatitis
|
CA3084582A1
(en)
|
2017-12-20 |
2019-06-27 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
|
AU2018392213B2
(en)
|
2017-12-20 |
2021-03-04 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein
|
JP7062792B2
(ja)
|
2018-02-13 |
2022-05-06 |
ギリアード サイエンシーズ, インコーポレイテッド |
Pd-1/pd-l1阻害剤
|
JP7083398B2
(ja)
|
2018-02-15 |
2022-06-10 |
ギリアード サイエンシーズ, インコーポレイテッド |
ピリジン誘導体およびhiv感染を処置するためのその使用
|
TWI823164B
(zh)
|
2018-02-16 |
2023-11-21 |
美商基利科學股份有限公司 |
用於製備有療效化合物之方法及中間物
|
PL3759109T3
(pl)
|
2018-02-26 |
2024-03-04 |
Gilead Sciences, Inc. |
Podstawione związki pirolizyny jako inhibitory replikacji hbv
|
TW201945003A
(zh)
|
2018-03-01 |
2019-12-01 |
愛爾蘭商健生科學愛爾蘭無限公司 |
2,4-二胺基喹唑啉衍生物及其醫學用途
|
US10870691B2
(en)
|
2018-04-05 |
2020-12-22 |
Gilead Sciences, Inc. |
Antibodies and fragments thereof that bind hepatitis B virus protein X
|
TW202005654A
(zh)
|
2018-04-06 |
2020-02-01 |
捷克科學院有機化學與生物化學研究所 |
2,2,─環二核苷酸
|
CN111954675A
(zh)
|
2018-04-06 |
2020-11-17 |
捷克共和国有机化学与生物化学研究所 |
3’3’-环二核苷酸
|
TWI818007B
(zh)
|
2018-04-06 |
2023-10-11 |
捷克科學院有機化學與生物化學研究所 |
2'3'-環二核苷酸
|
TW201945388A
(zh)
|
2018-04-12 |
2019-12-01 |
美商精密生物科學公司 |
對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶
|
WO2019204609A1
(en)
|
2018-04-19 |
2019-10-24 |
Gilead Sciences, Inc. |
Pd-1/pd-l1 inhibitors
|
WO2019211799A1
(en)
|
2018-05-03 |
2019-11-07 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
|
BR112020026890A2
(pt)
*
|
2018-07-03 |
2021-03-30 |
Jiangsu Hengrui Medicine Co., Ltd. |
Derivado de piridopirimidina, método de preparação do mesmo e uso médico do mesmo
|
EP3817819A1
(en)
|
2018-07-03 |
2021-05-12 |
Gilead Sciences, Inc. |
Antibodies that target hiv gp120 and methods of use
|
US11098027B2
(en)
|
2018-07-06 |
2021-08-24 |
Gilead Sciences, Inc. |
Therapeutic heterocyclic compounds
|
JP7199502B2
(ja)
|
2018-07-06 |
2023-01-05 |
ギリアード サイエンシーズ, インコーポレイテッド |
治療用複素環式化合物
|
CN112399874B
(zh)
|
2018-07-13 |
2024-03-22 |
吉利德科学公司 |
Pd-1/pd-l1抑制剂
|
TWI814350B
(zh)
|
2018-07-16 |
2023-09-01 |
美商基利科學股份有限公司 |
用於治療hiv之蛋白殼抑制劑
|
TW202011986A
(zh)
|
2018-07-23 |
2020-04-01 |
公益財團法人日本健康科學振興財團 |
包含流感疫苗之組合物
|
WO2020028097A1
(en)
|
2018-08-01 |
2020-02-06 |
Gilead Sciences, Inc. |
Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
|
KR20210081332A
(ko)
|
2018-09-12 |
2021-07-01 |
실버백 테라퓨틱스, 인크. |
면역 자극성 접합체를 사용한 질환의 치료를 위한 조성물
|
AU2019344868A1
(en)
*
|
2018-09-19 |
2021-04-15 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
TLR8 agonist
|
WO2020072656A1
(en)
|
2018-10-03 |
2020-04-09 |
Gilead Sciences, Inc. |
Imidozopyrimidine derivatives
|
KR102635333B1
(ko)
|
2018-10-24 |
2024-02-15 |
길리애드 사이언시즈, 인코포레이티드 |
Pd-1/pd-l1 억제제
|
TWI721623B
(zh)
|
2018-10-31 |
2021-03-11 |
美商基利科學股份有限公司 |
經取代之6-氮雜苯并咪唑化合物
|
CA3116347A1
(en)
|
2018-10-31 |
2020-05-07 |
Gilead Sciences, Inc. |
Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
|
BR112021015577A2
(pt)
|
2019-02-08 |
2021-10-05 |
Research & Business Foundation Sungkyunkwan University |
Complexo-colesterol agonista do receptor toll-like 7 ou 8 e uso do mesmo
|
WO2020176510A1
(en)
|
2019-02-25 |
2020-09-03 |
Gilead Sciences, Inc. |
Protein kinase c agonists
|
WO2020176505A1
(en)
|
2019-02-25 |
2020-09-03 |
Gilead Sciences, Inc. |
Protein kinase c agonists
|
WO2020178768A1
(en)
|
2019-03-07 |
2020-09-10 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
|
CN113543851A
(zh)
|
2019-03-07 |
2021-10-22 |
捷克共和国有机化学与生物化学研究所 |
2’3’-环二核苷酸及其前药
|
KR20210137518A
(ko)
|
2019-03-07 |
2021-11-17 |
인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. |
3'3'-사이클릭 다이뉴클레오티드 및 이의 프로드럭
|
WO2020205660A1
(en)
*
|
2019-03-29 |
2020-10-08 |
University Of Florida Research Foundation, Incorporated |
Prmt5 inhibitor compounds
|
TWI751516B
(zh)
|
2019-04-17 |
2022-01-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
TWI751517B
(zh)
|
2019-04-17 |
2022-01-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
TWI762925B
(zh)
|
2019-05-21 |
2022-05-01 |
美商基利科學股份有限公司 |
鑑別對使用gp120 v3聚醣導向之抗體的治療敏感之hiv病患的方法
|
EP3972695A1
(en)
|
2019-05-23 |
2022-03-30 |
Gilead Sciences, Inc. |
Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
|
CA3140708A1
(en)
|
2019-06-18 |
2020-12-24 |
Helen Horton |
Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
|
JP2022538398A
(ja)
*
|
2019-06-18 |
2022-09-02 |
ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー |
ウイルス感染症及び更なる疾患の処置用のキナゾリンプロドラッグ
|
WO2020255039A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and quinazoline derivatives
|
JP2022536855A
(ja)
|
2019-06-19 |
2022-08-19 |
シルバーバック セラピューティックス インコーポレイテッド |
抗メソテリン抗体およびそのイムノコンジュゲート
|
WO2020263830A1
(en)
|
2019-06-25 |
2020-12-30 |
Gilead Sciences, Inc. |
Flt3l-fc fusion proteins and methods of use
|
TW202115056A
(zh)
|
2019-06-28 |
2021-04-16 |
美商基利科學股份有限公司 |
類鐸受體調節劑化合物的製備方法
|
AU2020315598A1
(en)
|
2019-07-16 |
2022-03-03 |
Gilead Sciences, Inc. |
HIV vaccines and methods of making and using
|
WO2021011891A1
(en)
|
2019-07-18 |
2021-01-21 |
Gilead Sciences, Inc. |
Long-acting formulations of tenofovir alafenamide
|
EP4017476A1
(en)
|
2019-08-19 |
2022-06-29 |
Gilead Sciences, Inc. |
Pharmaceutical formulations of tenofovir alafenamide
|
AU2020333708C1
(en)
*
|
2019-08-19 |
2024-02-22 |
Shanghai Zhimeng Biopharma Inc. |
2-aminopyrimidine compounds and pharmaceutical compositions and uses thereof
|
AR120096A1
(es)
|
2019-09-30 |
2022-02-02 |
Gilead Sciences Inc |
Vacunas para vhb y métodos de tratamiento de vhb
|
CA3151322A1
(en)
|
2019-10-01 |
2021-04-08 |
Silverback Therapeutics, Inc. |
Combination therapy with immune stimulatory conjugates
|
MX2022004370A
(es)
|
2019-10-18 |
2022-05-06 |
Forty Seven Inc |
Terapias de combinacion para tratar sindromes mielodisplasicos y leucemia mieloide aguda.
|
CN114599392A
(zh)
|
2019-10-31 |
2022-06-07 |
四十七公司 |
基于抗cd47和抗cd20的血癌治疗
|
TWI778443B
(zh)
|
2019-11-12 |
2022-09-21 |
美商基利科學股份有限公司 |
Mcl1抑制劑
|
AU2020391466A1
(en)
|
2019-11-26 |
2022-07-07 |
Gilead Sciences, Inc. |
Capsid inhibitors for the prevention of HIV
|
US20230031465A1
(en)
|
2019-12-06 |
2023-02-02 |
Precision Biosciences, Inc. |
Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
|
WO2021130638A1
(en)
|
2019-12-24 |
2021-07-01 |
Carna Biosciences, Inc. |
Diacylglycerol kinase modulating compounds
|
IL295023A
(en)
|
2020-02-14 |
2022-09-01 |
Jounce Therapeutics Inc |
Antibodies and fusion proteins that bind to ccr8 and their uses
|
US11179473B2
(en)
|
2020-02-21 |
2021-11-23 |
Silverback Therapeutics, Inc. |
Nectin-4 antibody conjugates and uses thereof
|
WO2021177679A1
(ko)
|
2020-03-02 |
2021-09-10 |
성균관대학교산학협력단 |
병원균 외벽 성분 기반 생병원체 모방 나노 입자 및 그 제조 방법
|
AU2021237718B2
(en)
|
2020-03-20 |
2023-09-21 |
Gilead Sciences, Inc. |
Prodrugs of 4'-C-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
|
AU2021264550A1
(en)
|
2020-05-01 |
2022-11-17 |
Gilead Sciences, Inc. |
CD73 inhibiting 2,4-dioxopyrimidine compounds
|
EP4153181A1
(en)
|
2020-05-21 |
2023-03-29 |
Gilead Sciences, Inc. |
Pharmaceutical compositions comprising bictegravir
|
CN115996925A
(zh)
|
2020-06-25 |
2023-04-21 |
吉利德科学公司 |
用于治疗hiv的衣壳抑制剂
|
KR20230047361A
(ko)
|
2020-07-01 |
2023-04-07 |
아르스 파마슈티컬스 인크. |
항-asgr1 항체 접합체 및 이의 용도
|
JP2023536954A
(ja)
|
2020-08-04 |
2023-08-30 |
プロジェニア インコーポレイテッド |
活性化部位が一時的に不活性化したトール様受容体7または8作用薬と機能性薬物の結合体およびその用途
|
US20230355750A1
(en)
|
2020-08-04 |
2023-11-09 |
Progeneer Inc. |
Kinetically acting adjuvant ensemble
|
WO2022031021A1
(ko)
|
2020-08-04 |
2022-02-10 |
성균관대학교산학협력단 |
동력학적 제어가 가능한 아주번트를 포함하는 mrna 백신
|
IL299980A
(en)
|
2020-08-07 |
2023-03-01 |
Gilead Sciences Inc |
Preparations of phosphonamide nucleotide analogues and their medicinal use
|
TWI815194B
(zh)
|
2020-10-22 |
2023-09-11 |
美商基利科學股份有限公司 |
介白素2-Fc融合蛋白及使用方法
|
US20220144923A1
(en)
|
2020-11-11 |
2022-05-12 |
Gilead Sciences, Inc. |
METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH gp120 CD4 BINDING SITE-DIRECTED ANTIBODIES
|
CA3215049A1
(en)
|
2021-04-10 |
2022-10-13 |
Baiteng ZHAO |
Folr1 binding agents, conjugates thereof and methods of using the same
|
TW202302145A
(zh)
|
2021-04-14 |
2023-01-16 |
美商基利科學股份有限公司 |
CD47/SIRPα結合及NEDD8活化酶E1調節次單元之共抑制以用於治療癌症
|
TW202308699A
(zh)
|
2021-04-23 |
2023-03-01 |
美商普方生物製藥美國公司 |
Cd70結合劑、其結合物及其使用方法
|
KR20240006683A
(ko)
|
2021-05-13 |
2024-01-15 |
길리애드 사이언시즈, 인코포레이티드 |
TLR8 조절 화합물과 항-HBV siRNA 치료제의 조합물
|
US20220389394A1
(en)
|
2021-05-18 |
2022-12-08 |
Gilead Sciences, Inc. |
METHODS OF USING FLT3L-Fc FUSION PROTEINS
|
US11926628B2
(en)
|
2021-06-23 |
2024-03-12 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
CA3222439A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
WO2022271684A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
US11932634B2
(en)
|
2021-06-23 |
2024-03-19 |
Gilead Sciences, Inc. |
Diacylglycerol kinase modulating compounds
|
TW202320857A
(zh)
|
2021-07-06 |
2023-06-01 |
美商普方生物製藥美國公司 |
連接子、藥物連接子及其結合物及其使用方法
|
WO2023054759A1
(ko)
*
|
2021-09-30 |
2023-04-06 |
한국화학연구원 |
2-아미노퀴나졸린 유도체 및 이를 포함하는 항바이러스용 조성물
|
TW202330504A
(zh)
|
2021-10-28 |
2023-08-01 |
美商基利科學股份有限公司 |
嗒𠯤—3(2h)—酮衍生物
|
WO2023077030A1
(en)
|
2021-10-29 |
2023-05-04 |
Gilead Sciences, Inc. |
Cd73 compounds
|
CA3235937A1
(en)
|
2021-12-03 |
2023-06-08 |
Gilead Sciences, Inc. |
Therapeutic compounds for hiv virus infection
|
TW202342447A
(zh)
|
2021-12-03 |
2023-11-01 |
美商基利科學股份有限公司 |
用於hiv病毒感染之治療性化合物
|
TW202342448A
(zh)
|
2021-12-03 |
2023-11-01 |
美商基利科學股份有限公司 |
用於hiv病毒感染之治療性化合物
|
US20230203202A1
(en)
|
2021-12-08 |
2023-06-29 |
Dragonfly Therapeutics, Inc. |
Proteins binding nkg2d, cd16 and 5t4
|
US20230220106A1
(en)
|
2021-12-08 |
2023-07-13 |
Dragonfly Therapeutics, Inc. |
Antibodies targeting 5t4 and uses thereof
|
US20230242508A1
(en)
|
2021-12-22 |
2023-08-03 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
US20240124412A1
(en)
|
2021-12-22 |
2024-04-18 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
TW202340168A
(zh)
|
2022-01-28 |
2023-10-16 |
美商基利科學股份有限公司 |
Parp7抑制劑
|
WO2023178181A1
(en)
|
2022-03-17 |
2023-09-21 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
WO2023183817A1
(en)
|
2022-03-24 |
2023-09-28 |
Gilead Sciences, Inc. |
Combination therapy for treating trop-2 expressing cancers
|
TW202345901A
(zh)
|
2022-04-05 |
2023-12-01 |
美商基利科學股份有限公司 |
用於治療結腸直腸癌之組合療法
|
TW202400172A
(zh)
|
2022-04-06 |
2024-01-01 |
美商基利科學股份有限公司 |
橋聯三環胺甲醯基吡啶酮化合物及其用途
|
US20230374036A1
(en)
|
2022-04-21 |
2023-11-23 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
US20240034724A1
(en)
|
2022-07-01 |
2024-02-01 |
Gilead Sciences, Inc. |
Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
|
US20240116928A1
(en)
|
2022-07-01 |
2024-04-11 |
Gilead Sciences, Inc. |
Cd73 compounds
|
WO2024015741A1
(en)
|
2022-07-12 |
2024-01-18 |
Gilead Sciences, Inc. |
Hiv immunogenic polypeptides and vaccines and uses thereof
|
US20240083984A1
(en)
|
2022-08-26 |
2024-03-14 |
Gilead Sciences, Inc. |
Dosing and scheduling regimen for broadly neutralizing antibodies
|
US20240091351A1
(en)
|
2022-09-21 |
2024-03-21 |
Gilead Sciences, Inc. |
FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY
|
WO2024076915A1
(en)
|
2022-10-04 |
2024-04-11 |
Gilead Sciences, Inc. |
4'-thionucleoside analogues and their pharmaceutical use
|